Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.44 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.44 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.42 |
| ▸ | ACHE | P22303 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | BRD4 | O60885 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9321537 | 0.98 | L3MBTL1 (0.49) | L3MBTL1CYP1A2CHRM2CHRM4CHRM5 | |
| SCHEMBL874408 | 0.93 | — | — | |
| SCHEMBL10978509 | 0.88 | L3MBTL1 (0.43) | L3MBTL1CYP1A2CHRM2CHRM4CHRM5 | |
| SCHEMBL7625589 | 0.86 | L3MBTL1 (0.42) | L3MBTL1CYP1A2CHRM2CHRM4CHRM5 | |
| SCHEMBL10973569 | 0.84 | L3MBTL1 (0.41) | L3MBTL1CYP1A2CHRM2CHRM4CHRM5 | |
| SCHEMBL10976715 | 0.84 | L3MBTL1 (0.41) | L3MBTL1CYP1A2CHRM2CHRM4CHRM5 | |
| SCHEMBL10978986 | 0.84 | L3MBTL1 (0.41) | L3MBTL1CYP1A2CHRM2CHRM4CHRM5 | |
| SCHEMBL10978957 | 0.84 | L3MBTL1 (0.41) | L3MBTL1CYP1A2CHRM2CHRM4CHRM5 | |
| SCHEMBL10975229 | 0.84 | L3MBTL1 (0.41) | L3MBTL1CYP1A2CHRM2CHRM4CHRM5 | |
| SCHEMBL9654620 | 0.83 | L3MBTL1 (0.44) | L3MBTL1CYP1A2CHRM2CHRM4CHRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9181240-B2 | Tetracyclic compounds | MEDIVATION TECHNOLOGIES, INC. (US) | 2015-11-10 | — | — | US | disclosed |
| US-9096591-B2 | Tetracyclic compounds | MEDIVATION TECHNOLOGIES, INC. (US) | 2015-08-04 | — | — | US | disclosed |
| EP-2274307-B1 | BRIDGED HETEROCYCLIC COMPOUNDS AND METHODS OF USE | MEDIVATION TECHNOLOGIES INC (US) | 2015-07-29 | — | — | EP | disclosed |
| US-20150182509-A1 | TETRACYCLIC COMPOUNDS | MEDIVATION TECHNOLOGIES, INC. | 2015-07-02 | — | — | US | disclosed |
| US-9051314-B2 | Bridged heterocyclic compounds and methods of use | MEDIVATION TECHNOLOGIES, INC. (US) | 2015-06-09 | — | — | US | disclosed |
| US-9034869-B2 | Bridged heterocyclic compounds and methods of use | MEDIVATION TECHNOLOGIES, INC. (US) | 2015-05-19 | — | — | US | disclosed |
| US-9034880-B2 | Tetracyclic compounds | MEDIVATION TECHNOLOGIES, INC. (US) | 2015-05-19 | — | — | US | disclosed |
| US-8999977-B2 | Bridged heterocyclic compounds and methods of use | MEDIVATION TECHNOLOGIES, INC. (US) | 2015-04-07 | — | — | US | disclosed |
| US-8999978-B2 | Tetracyclic compounds | MEDIVATION TECHNOLOGIES, INC. (US) | 2015-04-07 | — | — | US | disclosed |
| US-20140194414-A1 | TETRACYCLIC COMPOUNDS | MEDIVATION TECHNOLOGIES, INC. (US) | 2014-07-10 | — | — | US | disclosed |
| US-20130190304-A1 | TETRACYCLIC COMPOUNDS | MEDIVATION TECHNOLOGIES, INC. (US) | 2013-07-25 | — | — | US | disclosed |
| US-20130184269-A1 | BRIDGED HETEROCYCLIC COMPOUNDS AND METHODS OF USE | MEDIVATION TECHNOLOGIES, INC. (US) | 2013-07-18 | — | — | US | disclosed |
| US-20130131054-A1 | TETRACYCLIC COMPOUNDS | MEDIVATION TECHNOLOGIES, INC. (US) | 2013-05-23 | — | — | US | disclosed |
| US-8338408-B2 | Tetracyclic compounds | MEDIVATION TECHNOLOGIES, INC. (US) | 2012-12-25 | — | — | US | disclosed |
| EP-2274307-A1 | BRIDGED HETEROCYCLIC COMPOUNDS AND METHODS OF USE | Medivation Technologies, Inc. (US) | 2011-01-19 | — | — | EP | disclosed |
| EP-2217598-A1 | NEW TETRACYCLIC COMPOUNDS | Medivation Technologies, Inc. (US) | 2010-08-18 | — | — | EP | disclosed |
| US-20100099667-A1 | BRIDGED HETEROCYCLIC COMPOUNDS AND METHODS OF USE | MEDIVATION TECHNOLOGIES, INC. | 2010-04-22 | — | — | US | disclosed |
| WO-2009120720-A1 | BRIDGED HETEROCYCLIC COMPOUNDS AND METHODS OF USE | MEDIVATION TECHNOLOGIES,INC. (US) | 2009-10-01 | — | — | WO | disclosed |
| US-20090239854-A1 | Tetracyclic compounds | MEDIVATION TECHNOLOGIES, INC. | 2009-09-24 | — | — | US | disclosed |
| WO-2009055828-A1 | NEW TETRACYCLIC COMPOUNDS | MEDIVATION TECHNOLOGIES, INC. (US) | 2009-04-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130184269-A1 | BRIDGED HETEROCYCLIC COMPOUNDS AND METHODS OF USE | HRH4, HNMT, HTR2C | L3MBTL1 4662/4885CYP1A2 1325/4885CHRM2 88/4885 |
| US-20150182509-A1 | TETRACYCLIC COMPOUNDS | HTR2C, HTR3D, HTR5A | L3MBTL1 3804/4885CYP1A2 2499/4885CHRM2 109/4885 |
| US-20130131054-A1 | TETRACYCLIC COMPOUNDS | HTR2C, HTR3D, HTR5A | L3MBTL1 3804/4885CYP1A2 2499/4885CHRM2 109/4885 |
| US-20130190304-A1 | TETRACYCLIC COMPOUNDS | HTR2C, HTR3D, HTR5A | L3MBTL1 3804/4885CYP1A2 2499/4885CHRM2 109/4885 |
| US-20100099667-A1 | BRIDGED HETEROCYCLIC COMPOUNDS AND METHODS OF USE | HRH4, HNMT, HTR2C | L3MBTL1 4662/4885CYP1A2 1325/4885CHRM2 88/4885 |
| US-20090239854-A1 | Tetracyclic compounds | HTR2C, HTR3D, HTR5A | L3MBTL1 3804/4885CYP1A2 2499/4885CHRM2 109/4885 |
| US-20140194414-A1 | TETRACYCLIC COMPOUNDS | HTR2C, HTR3D, HTR5A | L3MBTL1 3804/4885CYP1A2 2499/4885CHRM2 109/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.